Status:
COMPLETED
Molecular Staging of Endometrial Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study, sponsored by NCI and the Gynecologic Oncology Group (GOG), will collect tissue samples from women with cancer of the endometrium (lining of the uterus). Researchers will use the samples to...
Detailed Description
GOG-210 is a molecular and surgico-pathological staging study of endometrial carcinoma. The overall goal of this pilot protocol is to improve outcome and/or quality of life for patients with endometri...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients with endometrial carcinoma diagnosed by an endometrial biopsy or dilation and curettage who will undergo full surgical staging; all stages, grades and histologic subtypes will be eligible.
- Patients must be suitable candidates for surgery. Patients may also be entered on GOG-2222 (LAP2).
- Patients who have signed an approved Informed Consent.
- Patients who have met the pre-entry requirements specified in the Study Parameters.
- Patients with a prior malignancy (at least 5 years since diagnosis) with no current evidence of disease.
- EXCLUSION CRITERIA:
- Patients not considered suitable candidates for surgery.
- Patients who have had prior retroperitoneal surgery.
- Patients who have received prior pelvic or abdominal radiation therapy.
- Patients who are pregnant.
Exclusion
Key Trial Info
Start Date :
March 19 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 16 2020
Estimated Enrollment :
5492 Patients enrolled
Trial Details
Trial ID
NCT00340808
Start Date
March 19 2004
End Date
July 16 2020
Last Update
July 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oklahoma
Norman, Oklahoma, United States, 73019